Sevasemten not checked

Edgewise Therapeutics, Inc. · EDG-5506

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
9 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Duchenne Muscular Dystrophy (2 trials), Becker Muscular Dystrophy
Main trialPhase 2
“The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a randomized, double-blind, placebo-controlled part A, followed by an open-label part B.”In the company’s words, NCT05540860 on ClinicalTrials.gov
Other names
EDG-5506

Other drugs for Duchenne Muscular Dystrophy

All 23 drugs for Duchenne Muscular Dystrophy

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials9

TrialPhaseCompletesWhat it tests
Phase 2Active, not recruiting Jan 2027 A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)
Phase 2Active, not recruiting Mar 2027 Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy
Phase 2Enrolling by invitation Feb 2031 Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
Phase 2Completed 7 Sep 2026 Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
Phase 1Completed 15 Nov 2021 A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults
Phase 1Completed 19 Aug 2022 A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling
Phase 1Completed 6 Apr 2023 Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers
Phase 1Completed 1 Mar 2024 A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy
Phase 1Completed 22 Feb 2025 A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Sevasemten

Following is part of Solo: you see every change to Sevasemten the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in